

81085_Auto_Edited.docx

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 81085

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Intermediate-Term Outcomes of ABO-Incompatible Liver Transplantation in HIV-HBV Coinfected Patients with End-Stage Liver Disease

Outcomes of ABOi-LT in HIV-HBV patient

Jianxin Tang, Kangjun Zhang, Taishi Fang, Ruihui Weng, Ziming Liang, Xu Yan, Xin Jin, Linjie Xie, Xincheng Zeng, Dong Zhao

Abstract

BACKGROUND

Human immunodeficiency virus (HIV)-positive patients coinfecting with hepatitis B virus (HBV) are eligible for liver transplantation in Africa and Southeast Asia, particularly China. However, the outcome of HIV-HBV coinfecting patients referred for ABO-incompatible liver transplantation (ABOi-LT) is unknown.

AIM

To clarify the outcome of ABOi-LT for HIV-HBV coinfecting patients with end-stage liver disease.

METHODS

We reported two Chinese HIV-HBV coinfecting patients with end-stage liver disease who underwent A to O brain-dead donor liver transplantation and reviewed the literature on HIV-HBV coinfecting patients treated with ABO-compatible liver transplantation. The pretransplantation HIV viral load was undetectable, with no active opportunistic infections. Induction therapy consisted of two sessions of plasmapheresis and a single dose of rituximab in two split doses, followed by an intraoperative regimen of intravenous immunoglobulin, methylprednisolone, and basiliximab. Post-transplant maintenance immunosuppressive agents consisted of tacrolimus and mycophenolate mofetil, and prednisone.

RESULTS

At intermediate-term follow-up, patients showed undetectable HIV viral load, CD4(+) T cell counts greater than 150 cells/ μ L, no HBV recurrence, and stable liver function. A liver allograft biopsy showed no evidence of acute cellular rejection. Both patients survived at 36-42 mo of follow-up.

CONCLUSION

This is the first report of ABOi-LT in HIV-HBV recipients with good intermediate-term outcomes, suggesting that ABOi-LT may be feasible and safe for HIV-HBV coinfecting patients with end-stage liver disease.

Key Words: ABO incompatibility liver transplantation; Human immunodeficiency virus; Hepatitis B virus; End-stage liver disease; Immunosuppression

Tang J, Zhang K, Fang T, Weng R, Liang Z, Yan X, Jin X, Xie L, Zeng X, Zhao D. Intermediate-Term Outcomes of ABO-Incompatible Liver Transplantation in HIV-HBV Coinfecting Patients with End-Stage Liver Disease. *World J Gastroenterol* 2022; In press

Core Tip: The outcome of HIV-HBV coinfecting patients referred for ABO-incompatible liver transplantation (ABOi-LT) is unknown. We reported two Chinese HIV-HBV coinfecting patients with end-stage liver disease (ESLD) who underwent A to O brain-dead donor liver transplantation and reviewed the literature on HIV-HBV coinfecting patients treated with ABO-compatible liver transplantation. At intermediate-term follow-up, patients showed undetectable HIV viral load, CD4(+) T cell counts greater than 150 cells/ μ L, no HBV recurrence, and stable liver function. Both patients survived at 36-42 mo of follow-up. This is the first report of ABOi-LT in HIV-HBV recipients with good intermediate-term outcomes, suggesting that ABOi-LT may be feasible and safe for HIV-HBV coinfecting patients with ESLD.

4

INTRODUCTION

The recent introduction of highly active antiretroviral therapy (HAART) has dramatically changed the natural history of human immunodeficiency virus (HIV) infection^[1]. Both the mortality rate and the incidence of acquired immune deficiency syndrome (AIDS) due to HIV infection have decreased with effective suppression of viral replication and prophylaxis against opportunistic infections^[2]. However, HIV-infected patients are frequently coinfecting with hepatitis B virus (HBV) since both

viruses share similar modes of transmission, resulting in an increased risk of developing chronic liver disease^[3,4]. After the dramatic improvement in the survival of HIV-infected patients with HAART, hepatitis cirrhosis and its complications have replaced opportunistic infections as the leading cause of mortality in the HIV-HBV coinfecting patient^[5]. In addition, almost all of the antiretroviral agents are metabolized in the liver. Patients with hepatic metabolic impairment cannot use these agents, accounting for the increased mortality associated with AIDS^[6]. Accordingly, end-stage liver disease (ESLD) accounts for up to 50% of deaths in HIV-infected patients^[7,8]. It has long been thought that HIV is a contraindication to liver transplantation (LT) in the pre-HAART era since immunosuppression can reportedly aggravate HIV infection and complications^[9]. Case reports have shown nearly 25% AIDS-related mortality in HIV patients 6 mo after transplantation^[10,11]. However, an increasing body of evidence suggests comparable survival rates between HIV-positive and HIV-negative recipients after liver transplantation in the HAART era^[12-14]. These results suggest that HIV infection should not be a contraindication to LT, provided the underlying HIV disease is under control. Recent studies have shown that common indicators of controlled HIV disease-infected patient pretransplantation include HIV viral load < 200 copies/mm³, CD4(+) T cell count greater than 200 cells/ μ L, and absence of active opportunistic infections for at least 6 mo^[15]. ABO-incompatible (ABOi) LT is considered to be a high-risk procedure, compared to ABO-compatible LT, associated with a higher rate of antibody-mediated rejection (AMR), biliary complications, hepatic artery thrombosis, and mortality^[16]. Hence, ABO-incompatible liver grafts have been used as a rescue option. Advances in the treatment strategies for ABOi liver transplantation (ABOi-LT)^[17] include plasmapheresis, intravenous immunoglobulin (IVIG), splenectomy, rituximab, antilymphocyte antibodies, and immunosuppressant medications have improved the post-LT outcomes. The past decade has witnessed an increase in ABOi-LT procedures with increasing success. No significant difference between rejection and allograft survival at 1, 3, and 5 years after transplantation was found in a United Network of Organ Sharing Database

analysis between 1990 and 2010 that compared ABOi liver transplants with ABO-compatible transplants^[18].

Notably, the China Liver Transplant Registry (CLTR) does not prohibit HIV patients from receiving organs. With the introduction and effectiveness of HAART therapy, the outcomes of HIV-positive recipients with ESLD are reportedly similar to HIV-negative recipients after LT^[19]. However, the incompatibility between the ABO blood group and living organ donation severely limits the transplantation opportunities for this patient population^[20]. Besides, liver transplantation in HIV patients using ABOi organs brings additional complexity and difficulty to this already intricate patient population. Therefore, assessing the practicability of ABOi liver transplantation in HIV-positive recipients is essential. To our knowledge, ABOi liver transplantation in an HIV-HBV coinfecting recipient with ESLD has hitherto not been documented in the literature. Here, we report on two cases and review major clinical and research issues related to HIV-HBV coinfecting patients treated with ABO-compatible LT. We present the following article in accordance with the AME Case Series reporting checklist.

MATERIALS AND METHODS

From January 2019 to December 2021, 7 patients with HIV infection underwent liver transplantation in our LT center, including 2 patients with ABOi-LT. These 2 patients underwent ABOi-LT between April 2019 and December 2019, and their clinical data were extracted from our database. Both patients received HAART and anti-HBV therapy before transplantation and presented undetectable HIV RNA and HBV DNA levels, while the CD4(+) T cell count of one patient was less than 100 cells/ μ L. The surgical technique of ABOi-LT was a modified piggyback technique with triangulation of the hepatic veins. The vena cava anastomosis was completed with three separate continuous sutures, first completing the right side of the triangle. Subsequently, we released the vena cava blood flow to reduce the cold ischemia time. Next, we successively performed portal vein and hepatic artery vascular anastomosis. Bile duct reconstruction was performed by end-to-end anastomosis (continuous for the posterior

wall and interrupted for the anterior wall). The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This retrospective study was a single-center consecutive case series analysis approved by the Ethics Committee of the Third People's Hospital of Shenzhen (No. 2022-038-02). Written informed consent was obtained from all participants. To the best of our knowledge, no cases of ABO incompatibility involving HIV-HBV coinfection recipients have been reported in the literature. Little information is available on HIV-HBV coinfecting patients that undergo liver transplantation and methods to improve survival and reduce complications. We systematically searched for all patients diagnosed with HIV who underwent LT from 1995 to 2022. Search terms were (HIV OR human immunodeficiency virus) AND (HBV OR hepatitis B virus) AND (liver OR hepatic) AND (transplantation OR transplant) in Embase, MEDLINE, and PubMed. When data were missing, we contacted the study authors for additional information.

RESULTS

Clinical data of Patients
Case 1

A 61-year-old HIV-positive Chinese man with grade IV hepatic encephalopathy and hepatorenal syndrome secondary to decompensated HBV cirrhosis was referred for LT. He was considered a good candidate for LT because he had undetectable HIV RNA levels for at least 5 years, the CD4(+) T cell count was 42 cell/ μ L, and he received lamivudine and efavirenz as part of his Reverse Transcriptase inhibitor-based HAART therapy regimen for approximately 6 years. The model for end-stage liver disease (MELD) score was 40. However, given the absence of a suitable ABO-compatible liver donor and the patient's critical condition requiring urgent LT, a man with blood type A+ was used as the donor (O+ recipient, A+ donor). The recipient's latest anti-A titers were 1:128 for IgG and 1:32 for IgM before transplantation.

The decision was made to proceed with LT on April 4, 2019. Induction therapy consisted of two sessions of plasmapheresis, and rituximab 375 mg/m² in split doses was administered intravenously before surgery. Intravenous immunoglobulin (IVIG) 400mg/kg, rituximab 375 mg/m² in split doses, and methylprednisolone 0.5g were administered intravenously during the operation; and basiliximab 20 mg was administered intravenously prior to the release of circulation in the graft. Following transplantation, the patient was started on methylprednisolone for 7 days and switched to prednisone 48mg daily and tapered to 8mg daily over 4 wk. Maintenance immunosuppressive agents included tacrolimus and mycophenolate mofetil. Initially, 1mg tacrolimus twice daily was started on postoperative day (POD) 1 and titrated to achieve a trough of 12 to 15 ng/mL during the first 2 postoperative weeks. The tacrolimus dose was adjusted to maintain a concentration of 8 to 12 ng/mL from 2 wk to 1 mo after transplantation, 6 to 8 ng/mL within 1 to 6 mo after transplantation, and then 4 to 6 ng/mL for long-term follow-up in our institution. Mycophenolate mofetil was started on POD4 and adjusted reasonably according to the postoperative liver function, infection index, white blood cell count, and drug concentration. IVIG 400 mg/kg was given daily for 7 days, then every other day for two more sessions. In addition, the second dose of basiliximab 20mg was given on POD4. HAART therapy consisting of dolutegravir and lamivudine was restarted on POD1. Post-transplant ⁶ anti-HBV therapy included tenofovir alafenamide and monthly infusions of high-dose hepatitis B immune globulin (HBIG). Given the presence of HIV-associated immunodeficiency and antirejection medication use, infection prophylaxis is critical. The patient was treated with antibiotics, ganciclovir, and antifungal combination therapy. Due to a high preoperative anti-A IgM/IgG titer, the anti-A IgM/IgG titer, CD4(+) T lymphocyte count, postoperative rejection, and the risk of opportunistic infection after liver transplantation were dynamically monitored. From POD1, ABO blood group antibody titers and T lymphocyte subsets were detected in the blood collected from the patient every other day. Postoperative monitoring showed that anti-A IgG/IgM

decreased from 1:128/1:32 to 1:32/1:16 at 2 wk postoperatively (Figure 1A). There were no problems with postoperative infection and HIV management; the patient received post-transplant HAART and anti-HBV therapy with CD4(+) T cell counts ranging from 60 to 148 cells/ μ L with undetectable HIV RNA and HBV DNA levels. Allograft ultrasound showed normal blood vessels and biliary tract. Serum transaminase peaked at 458 U/L on POD1, then began to trend down. However, graft function worsened on POD14. Mild elevation of the hepatic enzymes (total bilirubin [Tbil], 97 μ mol/L; γ -glutamyltransferase [γ GT], 255 U/L; aspartate aminotransferase [AST], 39 U/L; alanine aminotransferase [ALT], 61 U/L) was observed (Figure 1B). The IgG and IgM titers remained stable (1:32 and 1:16, respectively). The follow-up liver allograft biopsy showed mild acute cellular rejection, with a Banff rejection activity index score of 4 (Figure 2). After the patient received intravenous pulse steroid therapy (80 mg of methylprednisolone for 3 days, then tapered), liver enzymes decreased and subsequently remained in the normal range. The patient was discharged on POD37 without any infection and exhibited normal liver function. On subsequent clinical follow-up, normal hepatic enzymes were maintained. His latest CD4(+) T cell count was 159 cells/ μ L on June 6, 2022. A follow-up liver biopsy 1 year after transplantation revealed no evidence of graft rejection. More than 3 years after LT, the patient and graft function remained stable.

Case

2

A 46-year-old HIV-HBV coinfecting Chinese man with acute-on-chronic liver failure was referred for LT. The preoperative Tbil was 320 μ mol/L, and the international normalized ratio (INR) was 9.85. A multidisciplinary team discussion concluded that he was considered a good candidate for emergency liver transplantation with a MELD score was 40 and received a HAART therapy regimen for approximately 3 years with undetectable HIV RNA levels and CD4(+) T cell count of 120 cells/ μ L. However, in the absence of suitable ABO-compatible liver donors, a man with blood type A+ was used as the donor (O+ recipient, A+ donor). The recipient's most recent anti-A titers for IgG and IgM were both 1:32 before transplantation. On November 19, 2019, the patient

underwent ABOi-LT in our LT center. The induction treatment and maintenance immunosuppression scheme is shown in patient 1. HAART therapy was restarted on POD 1 without changes. Given the immunodeficiency status of the patient treated with antirejection medication, the patient was treated with antibiotics, ganciclovir, and antifungal combination therapy for infection prophylaxis. The baseline anti-A IgG/IgM titers were both 1:32. Although the baseline anti-A titer was high and the CD4(+) T cell count was less than 200 cells/ μ L, an emergency ABOi LT was successfully performed. The anti-A IgG/IgM titer, CD4(+) T cell count, postoperative rejection, and the risk of opportunistic infection after LT were dynamically monitored. Postoperatively the anti-A IgG/IgM titers decreased from 1:32/1:32 to 1:16/1:4 at 2 wk. Postoperative infection was not observed, and HAART and anti-HBV therapy were continued; the post-transplant CD4(+) T cell counts ranged from 62 to 494 cells/ μ L with undetectable HIV RNA and HBV DNA levels. The patient was finally discharged on POD63 with normal liver function, IgG and IgM titers of 1:8 and 1:4, respectively, and the absence of any complications (Figure 3A). Deteriorating graft function was observed three months after LT, with relatively stable liver function (Tbil, 27 μ mol/L; AST, 32 U/L; ALT, 49 U/L). The blood drug concentration of tacrolimus was 3 ng/mL, and the CD4(+) T-cell count was 390 cells/ μ L. A follow-up liver biopsy at 6 mo after transplantation revealed no evidence of graft rejection. Twenty-five months after LT, he was hospitalized due to abnormal hepatic enzymes and underwent a liver biopsy. The pathology report suggested chronic cholangitis with bile duct sclerosis and the possibility of early chronic rejection (Figure 4). After the adjustment of the immunosuppressive drug regimen, the patient's liver function gradually stabilized. During the subsequent follow-up, the hepatic enzymes remained within the normal range with a CD4(+) T cell count of 467 cells/ μ L on February 7, 2022. Nearly 36 mo after LT, the patient and graft function remained stable.

Literature review

To date, there have been no reports of successful ABO-incompatible liver transplantation in HIV-HBV coinfecting patients. To understand the prognosis and risk

of HIV complications in patients with simultaneous HBV infection after liver transplantation, we reviewed the literature for LT in HBV-HIV coinfecting patients^[12-15,21-27]. Eleven studies were screened, reporting the characteristics of 69 patients with HIV-HBV coinfection that underwent liver transplantation from 1995 to 2022 (Table 1). The etiology of liver disease was HBV-related cirrhosis ($n = 62$) and fulminant liver failure due to HBV($n = 7$). Fifty-nine patients had HIV infection under control, with undetectable or low HIV viral loads and no previous AIDS events or opportunistic infections upon liver transplantation waiting list registration. ² At the time of transplantation, all but one patient had CD4(+) T cell counts above ≥ 100 cells/ μ L^[22]. Polymerase chain reaction showed that 17.4% of patients (12/69) had detectable HBV DNA prior to transplant (among these, 10 patients received adefovir and/or entecavir therapy, and 2 patients received lamivudine combined with tenofovir therapy). All patients received HAART following LT, plasma HIV-RNA remained low to undetectable in all patients (one case presented with a viral load of 76 copies/mL) ¹⁰ during follow-up. No viral breakthrough was observed. CD4(+) T cell counts were maintained at more than ≥ 100 cells/ μ L. All patients received dual immunoprophylaxis with hepatitis B immunoglobulin and anti-HBV medications. Eight patients tested positive for HBV DNA (among these, ⁵ low-level HBV viremia was intermittently detected in 7 patients ^[15] but not associated with HBsAg detection or ALT elevation; for one patient^[27] with a transiently positive HBV DNA, serum HBV DNA results were undetectable after tenofovir was added for antiviral therapy) (Table 1). 20.3% (14/69) of HIV-HBV coinfecting patients were treated with high-dose prednisone or adjustment of immunosuppressive therapy after developing acute cellular rejection. However, one patient^[23] died of hepatic artery thrombosis and graft failure due to rejection. The cumulative patient survival at one and three years in the HIV-HBV coinfecting patients was 85.9% and 77.3%, respectively.

DISCUSSION

Current evidence suggests that in the era of HAART therapy, morbidity and mortality have declined in HIV-infected patients^[28,29]. Mortality in this patient population is mainly attributed to comorbidities such as viral hepatitis infection, which is well-established to be associated with an increased prevalence of HIV-infected patients with ESLD. In recent years, studies have shown that the outcomes of HIV and non-HIV recipients were comparable, which has led to much controversy on transplantation in HIV patients^[15]. Multiple centers have established protocols for HIV recipients, including an undetectable HIV RNA viral load and CD4(+) T cell counts greater than 200 cells/ μ L for sustained HAART therapy without other contraindications to LT. Overwhelming evidence^[30-32] suggests promising outcomes for HAART-treated HIV-infected patients with maximally suppressed viral loads and no significant increase in opportunistic infections after LT. Although liver transplantation is more common in selected HIV recipients, no studies have reported ABO incompatibility involving HIV-HBV coinfecting recipients in the literature, while only 2 cases involving ABO-incompatible kidney transplantation have been reported in HIV recipients^[33,34]. Our study provides the first documented cases of A to O incompatible LT in HIV-HBV coinfecting recipients with ESLD. Ample evidence suggests that HIV-positive liver transplant recipients are prone to rejection due to immunosuppression or immune dysregulation from the virus itself^[35-37]. Interestingly, the United Network of Organ Sharing Database^[38] showed that the overall incidence of acute rejection in non-HIV recipients was 24.7% within 1 year after LT, which is similar to the incidence (20.3%) in our review of HIV-infected recipients. Regardless of the HIV infection status, acute rejection is common in ABOi transplantation, with an acute rejection rate of nearly 22%^[18]. In our report, emergency ABOi-LT was successfully performed in HIV-HBV coinfecting recipients that received induction therapy and adjunctive immunosuppressive regimens, including plasmapheresis, rituximab, basiliximab, methylprednisolone, and IVIG. Liver biopsy at mid-term follow-up did not show acute cellular rejection. The two patients described in our study are the first cases of A to O brain-dead donor

liver transplantation reported in the literature. The A-blood group is unique since it exhibits two phenotypes (A1 and A2) that harbor different immunogenicity. The A2 phenotype is characterized by reduced reactivity with anti-A isoagglutinin since it expresses fewer A epitopes on two of four possible core saccharide chains of the ABO antigen^[39]. Besides, an increasing body of evidence ^[40,41] suggests that transplantation of A2 Liver grafts does not elevate anti-A titers after liver transplantation. Kluger *et al* ^[18] reported that blood group O recipients with A2 grafts exhibited no significant differences in rejection during the transplant hospitalization and at 12 mo postoperatively, with the same overall and graft survival rates as recipients with O grafts at 1, 5, and 10 years. The patient's preoperative anti-A IgG/IgM titers in case 1 were 1:128 and 1:32, respectively. No definite graft rejection was observed 3 years after LT because the donor's blood group was A2. Our center's protocol for A to O liver transplantation is based on baseline (pretransplantation) titer data. If the anti-IgG and the IgM titers are >1:16, the preoperative management consists of two sessions of plasmapheresis, IVIG 400mg/kg, and rituximab 375 mg/m² in split doses. In our article, both patients received this protocol. Postoperative anti-A titer monitoring in patient 1 showed that anti-A IgG/IgM decreased from 1:128/1:32 pre-LT to 1:32/1:16 at 2 wk. During the subsequent three years of clinical follow-up, the patient exhibited normal liver enzyme levels. Preventing HBV recurrence and HIV progression has become a research hotspot in patients with HIV-HBV coinfection after liver transplantation. No consensus has been reached on the optimal anti-HBV therapy in patients with HIV-HBV coinfection. Anti-HIV drugs with anti-HBV activity include lamivudine, tenofovir, and emtricitabine. Drug therapy for HIV infection has important implications for preventing the recurrence of HBV infection. However, treating HBV infection in a coinfecting patient with lamivudine or tenofovir alone can result in HIV resistance to these drugs, affecting anti-HIV treatment options in the future^[42,43]. Accordingly, clinicians should be aware of the potential impact of nucleos(tide) analogue selection on managing HIV-HBV coinfecting recipients. Terrault *et al* ^[13] suggested that the combination therapy using

nucleos(t)ide analogues and HBIG in the HIV-HBV coinfecting recipient could effectively prevent post-transplantation HBV recurrence. In this report, the patient had excellent short outcomes after treatment with anti-HBV therapy, including tenofovir alafenamide and HBIG, and the HAART regimen consisting of dolutegravir and lamivudine. Subsequently, the two patients that underwent ABOi-LT with HIV were switched to albuvirtide and dolutegravir, well-recognized for their low hepatorenal toxicity and non-CYP450 enzyme inhibitors^[44], reducing the impact of calcineurin inhibitor-type immunosuppressive drugs, which achieved intermediate-term excellent outcomes. Overall, it is essential to continuously monitor HIV RNA and HBV DNA levels and optimize anti-HIV and anti-HBV therapies to reduce postoperative complications and prolong survival in HBV-HIV coinfecting recipients. Our HIV patients remained infection-free with good CD4(+) T cell count and stable liver function. Moreover, Albuvirtide and dolutegravir represent good options for HIV patients undergoing ABOi-LT.

Given that the number of HIV-infected patients with ESLD is expected to rise in the coming years, the same organ shortage issues that plague non-HIV patients will become increasingly severe for HIV patients^[45]. To our knowledge, these two cases are the first reports of ABOi-LT in HIV-HBV coinfecting patients with ESLD in the literature. In this study, the early course of ABOi-LT in HIV recipients was similar to that of ABO-compatible LT, without severe acute rejection. Desensitization regimens for ABOi-LT include rituximab, plasmapheresis, and intravenous immunoglobulin. In previous studies^[46,47] and our previous clinical practice, it has been observed that multiple doses of rituximab could increase the risk of infection, especially in immunodeficient HIV patients. Therefore, a sufficient dose and course of prophylactic antibiotics are crucial to prevent postoperative infection. Furthermore, the number of targeted B cells was significantly smaller in HIV transplant patients, and multiple doses of rituximab yielded no significant benefit for acute rejection or survival in transplant patients^[48], suggesting that a single dose of rituximab may be sufficient. The desensitization protocol is usually initiated 2 to 3 days before transplantation. In these two cases, we

administered a single dose of rituximab in two split doses, and two sessions of plasmapheresis were performed to reduce the anti-A titers with satisfactory results.

CONCLUSION

We successfully performed emergency ABOi-LT in HIV-HBV coinfecting patients. Their intermediate-term outcomes are encouraging, with normal graft function. Thus, ABOi-LT may be safe and feasible in HIV-HBV coinfecting patients with end-stage liver disease. We are cautiously optimistic that ABOi transplantation can be extended to other HIV-positive patients with end-stage liver disease.

ARTICLE HIGHLIGHTS

Research background

12

Human immunodeficiency virus (HIV)-positive patients coinfecting with hepatitis B virus (HBV) are eligible for liver transplantation in Africa and Southeast Asia, particularly China. However, the outcome of HIV-HBV coinfecting patients referred for ABO-incompatible liver transplantation (ABOi-LT) is unknown.

Research motivation

There have been no reports about the intermediate-term outcome of ABOi-LT in HIV-HBV coinfecting recipients.

Research objectives

We sought to clarify the outcome of ABOi-LT for HIV-HBV coinfecting patients with end-stage liver disease.

Research methods

We reported two Chinese HIV-HBV coinfecting patients with end-stage liver disease who underwent A to O brain-dead donor liver transplantation and reviewed the literature on HIV-HBV coinfecting patients treated with ABO-compatible liver

transplantation. Data of the pre- and post-transplantation were collected, including HIV viral load, CD4(+) T cell count, induction therapy methods, the immunosuppressive regimen and the clinical materials.

Research results

After follow-up for 36-42 mo, both patients survived, with undetectable HIV viral load, CD4(+) T cell counts greater than 150 cells/ μ L, no HBV recurrence, and stable liver function. Liver biopsy showed no evidence of acute cellular rejection.

Research conclusions

It is the first study of ABOi-LT in HIV-HBV recipients with good intermediate-term outcomes, which suggested that ABOi-LT may be feasible and safe for HIV-HBV coinfecting patients with end-stage liver disease.

3

Research perspectives

Due to the relatively small number of cases in the study, follow-up studies with large samples are still required.

ACKNOWLEDGEMENTS

We thank all the patients for cooperating with our investigation.

6%

SIMILARITY INDEX

PRIMARY SOURCES

- | | | |
|----------|---|-----------------|
| 1 | journals.lww.com
<small>Internet</small> | 100 words — 2% |
| <hr/> | | |
| 2 | publikationen.ub.uni-frankfurt.de
<small>Internet</small> | 30 words — 1% |
| <hr/> | | |
| 3 | Dong Zhao, Yi-Ming Huang, Zi-Ming Liang, Kang-Jun Zhang et al. "Reconstructing the portal vein through a posterior pancreatic tunnel: New choice for portal vein thrombosis during liver transplantation", World Journal of Gastrointestinal Surgery, 2022
<small>Crossref</small> | 26 words — 1% |
| <hr/> | | |
| 4 | www.europeanreview.org
<small>Internet</small> | 21 words — < 1% |
| <hr/> | | |
| 5 | Jack Harbell, Norah A. Terrault, Peter Stock. "Solid Organ Transplants in HIV-Infected Patients", Current HIV/AIDS Reports, 2013
<small>Crossref</small> | 18 words — < 1% |
| <hr/> | | |
| 6 | web.emmes.com
<small>Internet</small> | 15 words — < 1% |
| <hr/> | | |
| 7 | id.nii.ac.jp
<small>Internet</small> | 14 words — < 1% |
| <hr/> | | |
| 8 | www.ncbi.nlm.nih.gov
<small>Internet</small> | |

14 words — < 1%

9 Ian Schreiber, Jeffrey J. Gaynor, Dushyantha Jayaweera, Nikolaos Pysopoulos et al.
"Outcomes After Orthotopic Liver Transplantation in 15 HIV-Infected Patients", Transplantation, 2007

Crossref

13 words — < 1%

10 Mariagrazia Tateo. "Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfectd patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity", AIDS, 06/2009

Crossref

13 words — < 1%

11 liebertpub.com

Internet

13 words — < 1%

12 www.jove.com

Internet

12 words — < 1%

EXCLUDE QUOTES ON

EXCLUDE SOURCES < 12 WORDS

EXCLUDE BIBLIOGRAPHY ON

EXCLUDE MATCHES < 12 WORDS